EPM
JSPRW

Equitec Proprietary Markets’s Japer Therapeutics Warrants JSPRW Stock Holding History

Equitec Proprietary Markets’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-33,586
Closed -$4.13K – 133
2023
Q2 		$4.13K Sell
33,586
-11,270
-25% -$1.74K ﹤0.01% 81
2023
Q1 		$8.97K Sell
44,856
-1,000
-2% -$146 ﹤0.01% 91
2022
Q4 		$1.38K Hold
45,856
– – ﹤0.01% 167
2022
Q3 		$3K Hold
45,856
– – ﹤0.01% 207
2022
Q2 		$4K Hold
45,856
– – ﹤0.01% 208
2022
Q1 		$12K Hold
45,856
– – ﹤0.01% 169
2021
Q4 		$67K Buy
+45,856
New +$63.9K 0.01% 197

Other funds holding JSPRW

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
ICM
Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
ZA
Zazove Associates Incline Village, Nevada $1.22B AUM 1.92% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Equitec Proprietary Markets's JSPRW Position: Q3 2023 in Review

Equitec Proprietary Markets sold out of Japer Therapeutics Warrants (JSPRW) in Q3 2023, closing a stake of 33,586 shares — an estimated $4.13K sold.

Equitec Proprietary Markets first reported a position in JSPRW in Q4 2021 and held it in 7 quarters. The position peaked at $67K in Q4 2021. 8 funds tracked by Wall St. Rank hold JSPRW as of Q3 2023.

  • Equitec Proprietary Markets reported no remaining Japer Therapeutics Warrants position as of Q3 2023 after selling out during the quarter.
  • Equitec Proprietary Markets sold 33,586 Japer Therapeutics Warrants shares in Q3 2023, an estimated $4.13K.
  • Equitec Proprietary Markets first reported a position in Japer Therapeutics Warrants in Q4 2021 and held it in 7 quarters.
  • Equitec Proprietary Markets's Japer Therapeutics Warrants position peaked at $67K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q3 2023.

Based on Equitec Proprietary Markets's 13F filing for Q3 2023, filed 17 Oct 2023.